Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 15, 2009

Primary Completion Date

January 17, 2014

Study Completion Date

January 17, 2014

Conditions
Urinary IncontinenceBladder Dysfunction
Interventions
DRUG

Fesoterodine Oral Product

After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.

Trial Locations (1)

37232-2519

Vanderbilt Univiersity, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Saint Thomas Health

OTHER